Literature DB >> 27637310

The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy.

Allison P Wheeler1, David Gailani2.   

Abstract

Plasma coagulation in the activated partial thromboplastin time assay is initiated by sequential activation of coagulation factors XII, XI, and IX. While this series of proteolytic reactions is not an accurate model for hemostasis in vivo, there is mounting evidence that factor XI and factor XII contribute to thrombosis, and that inhibiting them can produce an antithrombotic effect with a small effect on hemostasis. This article discusses the contributions of components of the intrinsic pathway to thrombosis in animal models and humans, and results of early clinical trials of drugs targeting factors IX, XI, and XII.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Contact activation; Factor XI; Factor XII; Intrinsic pathway; Thrombosis

Mesh:

Substances:

Year:  2016        PMID: 27637310      PMCID: PMC5028121          DOI: 10.1016/j.hoc.2016.05.007

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  89 in total

1.  WATERFALL SEQUENCE FOR INTRINSIC BLOOD CLOTTING.

Authors:  E W DAVIE; O D RATNOFF
Journal:  Science       Date:  1964-09-18       Impact factor: 47.728

Review 2.  Factor IXa inhibitors as novel anticoagulants.

Authors:  Emily L Howard; Kristian C D Becker; Christopher P Rusconi; Richard C Becker
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-02-01       Impact factor: 8.311

3.  Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII.

Authors:  Carine J M Doggen; Frits R Rosendaal; Joost C M Meijers
Journal:  Blood       Date:  2006-08-24       Impact factor: 22.113

Review 4.  Medical device-induced thrombosis: what causes it and how can we prevent it?

Authors:  I H Jaffer; J C Fredenburgh; J Hirsh; J I Weitz
Journal:  J Thromb Haemost       Date:  2015-06       Impact factor: 5.824

Review 5.  Step-by-step evolution of vertebrate blood coagulation.

Authors:  R F Doolittle
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2009-08-10

6.  Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study.

Authors:  A Rumley; G D Lowe; P M Sweetnam; J W Yarnell; R P Ford
Journal:  Br J Haematol       Date:  1999-04       Impact factor: 6.998

7.  A coagulation factor IX-deficient mouse model for human hemophilia B.

Authors:  H F Lin; N Maeda; O Smithies; D L Straight; D W Stafford
Journal:  Blood       Date:  1997-11-15       Impact factor: 22.113

8.  First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.

Authors:  Christopher K Dyke; Steven R Steinhubl; Neal S Kleiman; Richard O Cannon; Laura G Aberle; Min Lin; Shelley K Myles; Chiara Melloni; Robert A Harrington; John H Alexander; Richard C Becker; Christopher P Rusconi
Journal:  Circulation       Date:  2006-11-13       Impact factor: 29.690

Review 9.  Elevated clotting factor levels and venous thrombosis.

Authors:  Rogier M Bertina
Journal:  Pathophysiol Haemost Thromb       Date:  2003 Sep-2004 Dec

10.  Defective thrombus formation in mice lacking coagulation factor XII.

Authors:  Thomas Renné; Miroslava Pozgajová; Sabine Grüner; Kai Schuh; Hans-Ulrich Pauer; Peter Burfeind; David Gailani; Bernhard Nieswandt
Journal:  J Exp Med       Date:  2005-07-11       Impact factor: 14.307

View more
  14 in total

Review 1.  Therapeutic strategies for thrombosis: new targets and approaches.

Authors:  Nigel Mackman; Wolfgang Bergmeier; George A Stouffer; Jeffrey I Weitz
Journal:  Nat Rev Drug Discov       Date:  2020-03-04       Impact factor: 84.694

Review 2.  Single-chain factor XII: a new form of activated factor XII.

Authors:  Ivan Ivanov; Anton Matafonov; David Gailani
Journal:  Curr Opin Hematol       Date:  2017-09       Impact factor: 3.284

Review 3.  Recent advances in the discovery and development of factor XI/XIa inhibitors.

Authors:  Rami A Al-Horani; Daniel K Afosah
Journal:  Med Res Rev       Date:  2018-05-04       Impact factor: 12.944

Review 4.  Targeting eukaryotic proteases for natural products-based drug development.

Authors:  Fatma H Al-Awadhi; Hendrik Luesch
Journal:  Nat Prod Rep       Date:  2020-06-24       Impact factor: 13.423

5.  Serum pharmacokinetics and coagulation aberration induced by sodium dehydroacetate in male and female Wistar rats.

Authors:  Yumei Zhang; Donglai Ying; Hao Liu; Zengrong Yu; Lingling Han; Jiayu Xie; Yang Xie
Journal:  Sci Rep       Date:  2017-04-07       Impact factor: 4.379

Review 6.  Factors XI and XII as Targets for New Anticoagulants.

Authors:  Jeffrey I Weitz; James C Fredenburgh
Journal:  Front Med (Lausanne)       Date:  2017-02-24

7.  Mechanisms of Bioactivities of Fucoidan from the Brown Seaweed Fucus vesiculosus L. of the Barents Sea.

Authors:  Olga N Pozharitskaya; Ekaterina D Obluchinskaya; Alexander N Shikov
Journal:  Mar Drugs       Date:  2020-05-22       Impact factor: 5.118

8.  Sinularin exerts anti-tumor effects against human renal cancer cells relies on the generation of ROS.

Authors:  Qi Ma; Xiang-Yu Meng; Ke-Rong Wu; Jian-Zhou Cao; Rui Yu; Ze-Jun Yan
Journal:  J Cancer       Date:  2019-08-28       Impact factor: 4.207

9.  Leveraging Human Genetics to Estimate Clinical Risk Reductions Achievable by Inhibiting Factor XI.

Authors:  Benjamin Georgi; Johanna Mielke; Mark Chaffin; Amit V Khera; Lian Gelis; Hardi Mundl; J J J van Giezen; Patrick Ellinor; Sekar Kathiresan; Karl Ziegelbauer; Daniel F Freitag
Journal:  Stroke       Date:  2019-09-27       Impact factor: 7.914

Review 10.  Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.

Authors:  Georg Gelbenegger; Christian Schoergenhofer; Paul Knoebl; Bernd Jilma
Journal:  Thromb Haemost       Date:  2020-07-27       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.